NCT00587730

Brief Summary

The accuracy of stress single photon emission computed tomography (SPECT) is limited by imaging artifacts, many of which are caused by soft tissue attenuation. A recent multicenter study performed by our laboratory comparing 7 commercially available attenuation correction (AC) camera systems in a cardiac phantom showed the best performance with the GE Hawkeye (a hybrid gamma camera-CT scanner) and the University of Michigan M-step (unique feature a camera orbit of 360˚ versus the usual 180˚) systems. In this study we will combine the strengths of these two systems (GE Hawkeye AC system and 360˚ camera orbit) to test the accuracy of this imaging system in a population of 400 consecutive patients undergoing clinically indicated stress SPECT. These patients will undergo SPECT imaging both with conventional methodology and the GE Hawkeye system. The conventional study will be interpreted and reported in the usual clinical fashion. The GE Hawkeye images will be interpreted independently by 2 observers blinded to the results of conventional imaging and will not be reported clinically. The primary study hypothesis is that AC will substantially reduce attenuation artifacts (mild fixed defects) without reducing the accuracy of either normal studies or myocardial infarction (MI). Clinical data and noninvasive test results (history of MI, electrocardiogram, and gated wall motion) will be used to distinguish defects which represent attenuation (false-positive) versus those due to MI (true-positive).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
608

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2001

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2001

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2004

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2004

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

December 21, 2007

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 7, 2008

Completed
Last Updated

April 23, 2015

Status Verified

April 1, 2015

Enrollment Period

3.1 years

First QC Date

December 21, 2007

Last Update Submit

April 21, 2015

Conditions

Keywords

heart diseasecardiac diseasechest painmyocardial infarctionheart attack

Outcome Measures

Primary Outcomes (1)

  • The overall comparisons of the agreement between conventional SPECT imaging and the GE Hawkeye system will be completed using McNemar's test.

    Measured/Compared at time of each scan.

Secondary Outcomes (1)

  • Comparisons of categorical factors between the 2 tests will also be completed using McNemar's test, continuous factors will be completed using a paired t-test if the differences are normally distributed.

    Measured/Compared at time of study

Study Arms (1)

Clinical SPECT

ACTIVE COMPARATOR

GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.

Device: GE Attenuation Corrected Hawkeye Camera

Interventions

GE Hawkeye AC system and 360˚ camera orbit

Clinical SPECT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients referred to the Charlton Nuclear Cardiology Laboratory for stress Tc-99m sestamibi SPECT

You may not qualify if:

  • Prior PTCA or CABG
  • Left bundle branch block (LBBB) or paced ventricular rhythm
  • Clinically significant valvular heart disease
  • Hypertrophic or idiopathic dilated cardiomyopathy
  • Atrial fibrillation or frequent atrial or ventricular ectopy (defined as \>20% ectopic beats
  • History of MI
  • ECG evidence of MI
  • Chest circumference \>55 inches

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Heart DiseasesChest PainMyocardial Infarction

Condition Hierarchy (Ancestors)

Cardiovascular DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMyocardial IschemiaVascular DiseasesInfarctionIschemiaPathologic ProcessesNecrosis

Study Officials

  • Todd D Miller, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 21, 2007

First Posted

January 7, 2008

Study Start

July 1, 2001

Primary Completion

August 1, 2004

Study Completion

August 1, 2004

Last Updated

April 23, 2015

Record last verified: 2015-04

Locations